Today: 27 January 2026
Subscribe
Browse Category

NASDAQ:TVTX News 6 January 2026 - 13 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as…
13 January 2026
·····
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

New York, January 13, 2026, 14:17 (EST) — Regular session Shares of Travere Therapeutics (TVTX.O) dropped 19% to $27.56 in early afternoon trading Tuesday after the U.S. Food and Drug Administration extended its review of the kidney drug Filspari for broader use. The stock had fallen as much as 34% earlier, hitting a low of $22.35. (Reuters) The delay comes…
13 January 2026
····
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan) into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and…
6 January 2026
·····

Stock Market Today

  • Is American Express (AXP) Fairly Valued After Recent Pullback?
    January 27, 2026, 3:18 AM EST. American Express (AXP) shares have pulled back modestly, falling about 0.4% over the past week and 4.7% in the last month, despite delivering a 16% return in the past year. The stock trades near US$363, close to Simply Wall St's Excess Returns model fair value estimate of US$361.44, suggesting it is about 0.5% overvalued-essentially fairly priced. This model considers factors like book value, earnings per share (EPS), return on equity (ROE), and cost of equity to measure the company's profitability above shareholder requirements. Investors continue to weigh American Express's strong premium customer base and its long-term growth, which has generated returns exceeding 100% over five years. The valuation balance could shift quickly, warranting close monitoring amid economic and industry changes.
Go toTop